Investigational Drug Information for Rintatolimod
✉ Email this page to a colleague
What is the drug development status for Rintatolimod?
Rintatolimod is an investigational drug.
There have been 20 clinical trials for Rintatolimod.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Colorectal Neoplasms. The leading clinical trial sponsors are AIM ImmunoTech Inc., Roswell Park Cancer Institute, and National Cancer Institute (NCI).
Summary for Rintatolimod
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 4,647 |
WIPO Patent Applications | 1,443 |
Japanese Patent Applications | 807 |
Clinical Trial Progress | Phase 2 (2016-03-01) |
Vendors | 6 |
Recent Clinical Trials for Rintatolimod
Title | Sponsor | Phase |
---|---|---|
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions | Amarex Clinical Research | Phase 2 |
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions | AIM ImmunoTech Inc. | Phase 2 |
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer | Roswell Park Cancer Institute | Phase 1/Phase 2 |
Clinical Trial Summary for Rintatolimod
Top disease conditions for Rintatolimod
Top clinical trial sponsors for Rintatolimod
US Patents for Rintatolimod
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |